pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,531 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT979Endpoints751BioPharma Dive287BioSpace188Fierce Biotech182onclive165globenewswire health73raps
therapy area
allOncology5732Rare Disease1266Cardiology1065Immunology964Hematology952Pulmonology846Vaccines
  • IRS probes UnitedHealth tax filings and private-equity deals for doctor groups slow down
    UnitedHealth disclosed that the IRS has opened an investigation into its tax filings for 2017-2020, seeking to increase the company’s taxable income and potentially raise its tax bill for those yea…
    STAT · 4h agoRegulatoryNegative↗ source
  • Akeso and Summit’s lung cancer candidate shows worsening tumor progression, while Europe halts Tavneos over trial concerns
    Akeso Therapeutics and Summit Therapeutics reported that their combined lung cancer therapy failed to improve outcomes, with data indicating a worsening in tumor progression compared to control. T…
    STAT · 5h agoNegative readoutNegative↗ source
← prev
page 1 of 62
next →
66
fda recalls41
fda medwatch32
fda press25
826
Psychiatry & CNS698
Ophthalmology371
Pain344
Endocrinology & Metabolism343
Infectious Disease334
  • AstraZeneca halts late-stage trial of volrustomig in metastatic lung cancer
    AstraZeneca said it is stopping a late-stage study of its experimental drug volrustomig combined with chemotherapy in patients with metastatic non-small cell lung cancer. The company made the decis…
    STAT · 6h agoNegative↗ source
  • Epic faces antitrust lawsuits and internal AI strategy turmoil ahead of annual user meeting
    Epic Systems, founded by Judy Faulkner, dominates the U.S. hospital electronic health record market and convenes its annual User Group Meeting with more than 20,000 attendees. The upcoming gatheri…
    STAT · 11h agoRegulatoryNegative↗ source
  • IRS launches probe into UnitedHealth over alleged tax avoidance from 2017-2020
    UnitedHealth Group is under investigation by the Internal Revenue Service, which says the insurer underpaid taxes by moving money to a foreign subsidiary during 2017-2020. The IRS is seeking to in…
    STAT · 11h agoRegulatoryNegative↗ source
  • Eli Lilly signs up to $370M ion-channel collaboration with OmniAb
    Eli Lilly has entered a collaboration with antibody platform company OmniAb that could involve up to $370 million in research, development and commercial milestone payments. OmniAb, which was spun…
    Fierce Biotech · 11h agoDealPositive↗ source
  • AstraZeneca halts phase 3 lung cancer trial of bispecific antibody volrustomig after it falls short of Keytruda
    AstraZeneca stopped its phase 3 trial of the bispecific antibody volrustomig in metastatic non‑small cell lung cancer after interim data suggested the regimen would not meet the study's primary goa…
    Fierce Biotech · 15h agoNegative readoutNegative↗ source
  • North Carolina’s bipartisan Medicaid pilot shows social services can cut health costs
    The article, written by former state health secretaries Mandy Cohen and Kody Kinsley, says North Carolina’s health‑care affordability crisis was tackled through a bipartisan pilot. The Healthy Opp…
    STAT · 11h agoPositive↗ source
  • FDA clears Lantheus' Tauklarify PET imaging agent for Alzheimer’s tau detection
    Lantheus received FDA clearance for its PET imaging agent Tauklarify, also known as MK-6240, which is designed to help diagnose Alzheimer’s disease by visualizing tau protein deposits. The clearan…
    Fierce Biotech · 11h agoRegulatoryPositive↗ source
  • State Laws Cut Private-Equity Acquisitions of Physician Practice Management Firms in Half
    State regulators in more than a dozen states have enacted laws that tighten oversight of private‑equity deals in health care, according to a new report. The tighter rules are reported to be slowing…
    STAT · 15h agoRegulatoryNeutral↗ source
  • Trump administration issues executive order overhauling federal vaccine program, drawing WHO criticism
    President Trump signed an executive order on Monday that reshapes the federal vaccine agenda, proposing changes that officials say lack supporting evidence. The World Health Organization publicly…
    STAT · 7h agoRegulatoryNegative↗ source
  • RFK Jr. contrasts vaccine push in D.C. with addiction-treatment focus in California
    In Washington, the health secretary stood beside the president as an executive order was signed to overhaul childhood vaccination policy. The scene highlighted his push for broader vaccine adoption…
    STAT · 11h agoNeutral↗ source
  • Paid paternity leave framed as preventive pediatric care in new opinion piece
    Pediatrician Nishant Pandya shares a recent clinic scene where a new father had to return to work the day after his daughter’s birth, highlighting the tension many families face. He notes that whi…
    STAT · 11h agoPositive↗ source
  • STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition
    Sanofi, one of the Massachusetts' largest pharmaceutical employers, will lay off more than 200 workers there a year after acquiring Blueprint Medicines.
    STAT · 12m ago↗ source
  • STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise
    Eyepoint said patients given its experimental treatment for wet AMD failed to maintain vision with less frequent injections compared to a standard treatment.
    STAT · 50m ago↗ source
  • Regeneron ends eye disease trial for anti-CD3 antibody following safety review
    Regeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event that tilted the drug’s risk/benefit profile in the wrong direction.
    Fierce Biotech · 5h ago↗ source
  • Merck KGaA lays off 20 staffers in latest blow to US research team
    The Massachusetts research site for Merck KGaA’s North American division, EMD Serono, has decided to hand pink slips to 20 staffers, Fierce has learned.
    Fierce Biotech · 6h ago↗ source
  • Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
    Slate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth and ahead of the publication of clinical data on its lead c…
    Fierce Biotech · 10h ago↗ source
  • Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidate
    Evaxion has scrapped a next-gen solid tumor vaccine in order to channel resources to a candidate specifically targeting brain cancer.
    Fierce Biotech · 10h ago↗ source
  • Baylor Genetics hit by cybersecurity attack targeting patient, staff information
    Diagnostic genomics company Baylor Genetics has become the latest victim of a life sciences cybersecurity breach, with both patients and employees affected.
    Fierce Biotech · 12h ago↗ source
  • Experts propose safety framework for improving predictability, interpretation of CNS toxicity
    The use and implementation of new approach methodologies (NAMs) and digital technologies such as artificial intelligence (AI) may help improve the predictability and interpretation of central nervo…
    raps · 19h ago↗ source
  • FDA approves Bristol Myers' first oral therapy for advanced multiple myeloma, a new drug class
    The U.S. Food and Drug Administration gave its nod to an oral medication from Bristol Myers Squibb for patients with advanced multiple myeloma. The drug represents the first member of a novel clas…
    STAT · 3d agoApprovalPositive↗ source
  • FDA clears Bristol Myers' Zenbexus, first drug of a new class for advanced multiple myeloma
    The FDA announced approval of an oral therapy from Bristol Myers Squibb for patients with advanced multiple myeloma. The drug, iberdomide, will be marketed as Zenbexus and is intended to be used t…
    STAT · 3d agoApprovalPositive↗ source
  • FDA grants accelerated approval to Bristol's Zenbexus for multiple myeloma; PBMs adopt TrumpRx pricing; Novartis wins UK Entresto patent
    The U.S. Food and Drug Administration granted accelerated approval to Bristol Myers Squibb's oral therapy Zenbexus for patients with advanced multiple myeloma. The drug represents a new class of tr…
    STAT · 3d agoApprovalPositive↗ source
  • Drug-testing lab sues US Pharmacopeia over alleged false statements about testing methods
    Valisure, a laboratory known for testing drug impurities, has filed a lawsuit in a U.S. court accusing the United States Pharmacopeia (USP) of making false and misleading statements about its testi…
    STAT · 3d agoRegulatoryNegative↗ source